Overview & Mechanism
Upregulates T-cell maturation and dendritic cell function, stimulates Toll-like receptors, and promotes a Th1 immune response; used as an immunomodulator in chronic infections and cancer.
Research Dosage
1.6 mg per dose
Subcutaneous injection
Twice weekly
Per protocol (often 6ā12 months)
Reconstitution & Storage
Reconstitute per vial with provided diluent or bacteriostatic water immediately before use.
Lyophilized: refrigerate 2ā8 °C. Reconstituted: use promptly per manufacturer.
Safety & Side Effects
Generally well tolerated; mild injection-site reactions. Approved in some countries for hepatitis B/C.
Studies
Thymosin alpha-1 in chronic hepatitis B
Thymosin alpha-1 improved virological response in chronic hepatitis B patients with minimal adverse effects.
Read studyReferences
Research Use Only
This information is intended for licensed researchers and educational purposes only. It does not constitute medical advice. PureLife Health products are not approved for human use by Health Canada or the FDA. Always consult a qualified medical professional and verify against current literature.